Company Filing History:
Years Active: 2014-2015
Title: Innovations of Andrew David Carr in Kinase Inhibitors
Introduction
Andrew David Carr is a notable inventor based in Great Chesterford, GB. With a portfolio of two patents, he has made significant contributions to the field of science, particularly in the development of kinase inhibitors.
Latest Patents
Among his latest patents is the innovative compound related to oxazole tyrosine kinase inhibitors. This invention provides a compound represented by an amide formula (1), or its various forms such as salts, solvates, N-oxides, or tautomers. The compound features specific parameters where 'a' is 0 or 1, 'b' is also 0 or 1, under the condition that the sum of a and b is 0 or 1. Furthermore, it entails a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group that can include up to four heteroatoms, being optionally substituted by various R groups. This innovation is significant as it focuses on inhibiting kinases, specifically FLT3, FLT4, and Aurora kinases, which hold prominence in cancer research and treatment.
Career Highlights
Andrew David Carr is currently affiliated with Sareum Limited, a company known for its pioneering work in medicinal chemistry and discovery of innovative therapeutics. His role contributes to the advancement of science through his inventions and solutions in kinase inhibitor development.
Collaborations
Throughout his career, Andrew has collaborated with notable colleagues, including John Charles Reader and John Mark Ellard. These partnerships have likely contributed to the innovative environment within which he operates, enabling a collective approach to scientific discoveries.
Conclusion
In summary, Andrew David Carr stands out as a proficient inventor in the realm of kinase inhibitors. His groundbreaking patents, coupled with his leadership and collaborative efforts at Sareum Limited, illustrate his dedication to scientific advancement. As research continues in this vital field, Carr's innovations may play a crucial role in the development of effective treatments for various cancers, ultimately benefiting patients worldwide.